Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Optune NovoTTF-200A System · 1 trial · 2 indications
Number of participants receiving treatment with the Optune NovoTTF-200A System with treatment-related adverse events as assessed by CTCAE v4.0.
Number of participants receiving treatment with the Optune NovoTTF-200A System with who return tolerability questionnaire and found the device tolerable
| Arm | Type | Description |
|---|---|---|
| Recurrent high grade gliomas and ependymomas | EXPERIMENTAL | Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy. Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab. |
| Name | Type | Description |
|---|---|---|
| Optune NovoTTF-200A System | DEVICE | Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab. |
Inclusion Criteria: * Patients must have a minimum head circumference of 44 cm * Patients must have a histologically- or cytologically-confirmed supratentorial high-grade glioma or supratentorial ependemoma. * Patients with metastatic disease involving the infratentorium or spinal cord are eligible...
The Optune NovoTTF-200A System is an investigational device being studied for use in high grade glioma, a type of brain cancer. It is also being evaluated for ependymoma. The device is currently in Phase 1 clinical development and is not yet approved for these indications.
The Optune NovoTTF-200A System is developed by NovoCure Limited, a company traded on the stock exchange under the ticker NVCR. NovoCure is conducting clinical research to evaluate the device's safety and potential efficacy in patients with high grade glioma.
The Optune NovoTTF-200A System is in Phase 1 clinical development. It is an investigational device, meaning it has not yet received regulatory approval. A Phase 1 trial has been completed to assess its use in patients with high grade glioma and ependymoma.
The Optune NovoTTF-200A System has been studied in one clinical trial with the identifier NCT03128047. This Phase 1 trial, titled 'HUMC 1612: Optune NovoTTF-200A System', was completed in the United States and enrolled 7 patients with high grade glioma or ependymoma.
The Optune NovoTTF-200A System is a specific device developed by NovoCure. While it shares the Optune brand name with other NovoCure products, it is a distinct system being evaluated in early-stage clinical trials for high grade glioma and ependymoma.